Sanofi hit by erosion of diabetes franchise

Sanofi SA reported higher revenue from its multiple sclerosis drugs and paediatric vaccines in the third quarter, which helped offset a decline in US sales of diabetes products. It has downgraded its forecast for diabetes products while warning of an accelerated decline in the fourth quarter.

Full text available to subscribers only. Click here for information on subscribing to MedNous.